Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol

May 15, 2024

https://www.globenewswire.com/news-release/2024/05/15/2882856/0/en/Eyenovia-Reports-First-Quarter-2024-Financial-Results-and-Provides-Updates-on-its-Myopia-Phase-III-Program-and-its-Two-FDA-Approved-Commercial-Products-Mydcombi-and-Clobetasol.html

Remains on track towards accelerating development of its late-stage product candidate in the multi-billion-dollar pediatric progressive myopia market, MicroPine

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.